Please select a Capability in order to start your service request.
Also Introduces the pink Achieve® Breast Biopsy DeviceMar 24, 2014
SAN DIEGO, CA, March 24, 2014 – CareFusion (NYSE:CFN), a leading global medical technology company, launched its new AVAflex ® Vertebral Balloon System today at the 39th annual Scientific Meeting of the Society of Interventional Radiology (SIR).
The new system is the latest innovation in CareFusion’s AVAmax® Advanced Vertebral Augmentation portfolio. The focus of these products is to provide a minimally invasive solution to treat vertebral compression fractures, while also promoting safety for the patient, physician and staff. The AVAflex Vertebral Balloon System combines the unique features of the AVAflex Curved Vertebral Augmentation Needle and the AVAmax Vertebral Balloon to enable targeted balloon placement across the midline of the vertebral body, followed by targeted cement placement for optimal fill through a single pedicle.
“Our new AVAflex Vertebral Balloon System has a curved needle and balloon, featuring a flexible tip that is designed to target balloon placement and ultimately target cement placement,” said Michael Voss, senior vice president and general manager of Interventional Specialties for CareFusion. “The system also has the ability to create multiple cavities through a single insertion site, which can help minimize patient trauma.”
The new AVAflex Vertebral Balloon System is available in 15mm and 20mm balloon sizes, with a 30mm option to be launched in the coming months.
Additional CareFusion technologies and products debuting at SIR include:
CareFusion will be exhibiting these new technologies at the SIR Scientific Meeting in booth 409.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.
1 Arendt, K., Demaerschalk, D., Wingerchuk, M. et al. “Atraumatic lumbar puncture needles: After all these years, are we still missing the point?” Neurologist, January 2009,15(1):17–20.